Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C

Clinical Trials

Volumn 9, Issue 1, 2012, Pages 102-112

  Reddy, K Rajender ^a   Belle, Steven H ^b   Fried, Michael W ^c   Afdhal, Nezam ^d   Navarro, Victor J ^e   Hawke, Roy L ^c   Wahed, Abdus S ^b   Doo, Edward ^f   Meyers, Catherine M ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; PLACEBO; RIBAVIRIN; SILIBININ; SILIBININ A; SILIBININ B; SILYMARIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; RESEARCH DESIGN; SILYMARIN;

EID: 84857067107     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511427064     Document Type: Conference Paper

References (38)

1. Armstrong GL, Wasley A, Simard EP, et al. The revalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 ; 144: 705-14 (Pubitemid 46780630)
2. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010 ; 138: 513-21
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001 ; 358: 958-65 (Pubitemid 32913521)
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 ; 347: 975-82
5. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 ; 140: 346-55
6. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat. 2005 ; 12: 81-5 (Pubitemid 40188778)
7. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002 ; 136: 288-92 (Pubitemid 34150758)
8. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003 ; 37: 443-51 (Pubitemid 36152544)
9. Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: A Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol. 2003 ; 98: 538-44 (Pubitemid 36348522)
10. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: A systematic review. J Viral Hepat. 2005 ; 12: 559-67 (Pubitemid 41532486)
11. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases-A systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol. 2005 ; 100: 2583-91
12. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008 ; 135: 1561-7
13. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998 ; 93: 139-43 (Pubitemid 29063954)
14. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008 ; 12: 1-23
15. Boigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology. 1997 ; 26: 643-9 (Pubitemid 27392355)
16. Jia JD, Bauer M, Cho JJ, et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol. 2001 ; 35: 392-8 (Pubitemid 32844194)
17. Polyak SJ, Morishima C, Shuhart MC, et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized silymarin. Gastroenterology. 2007 ; 132: 1925-36 (Pubitemid 46677939)
18. Tsai JH, Liu JY, Wu TT, et al. Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. J Viral Hepat. 2008 ; 15: 508-14 (Pubitemid 351798986)
19. Morishima C, Shuhart MC, Wang CC, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010 ; 138: 671-81
20. Polyak SJ, Morishima C, Lohmann V, et al. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA. 2010 ; 107: 5995-9
21. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2010 ; 138: 1112-22
22. Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010 ; 50: 434-49
23. Fried MW. Side effects of therapy for hepatitis C and their management. Hepatology. 2002 ; 36: S237-44
24. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002 ; 122: 1303-13 (Pubitemid 34465173)
25. Bonis PA, Ioannidis JP, Cappelleri JC, Kaplan MM, Lau J. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A meta-analysis of diagnostic test characteristics. Hepatology. 1997 ; 26: 1035-44 (Pubitemid 27413676)
26. Carithers RL, Emerson SS. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials. Hepatology. 1997 ; 26: 83S - 8S
27. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991 ; 101: 497-502
28. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology. 1997 ; 26: 780-5 (Pubitemid 27392374)
29. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998 ; 352: 1426-32 (Pubitemid 28510876)
30. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 ; 339: 1485-92 (Pubitemid 28543496)
31. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000 ; 32: 1131-7
32. Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos. 2008 ; 36: 1909-16
33. Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 ; 49: 1838-46
34. Sulkowski MS, Harrison SA, Rossaro L, et al. Impaired fasting glucose is associated with lower rates of sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C (CHC): Retrospective analysis of the IDEAL study. Hepatology. 2010 ; 52: 712A
35. Reddy KR, Shiffman ML, Rodriguez-Torres M, et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology. 2010 ; 139: 1972-83
36. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006 ; 131: 470-7 (Pubitemid 44142464)
37. Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol. 2004 ; 2: 469-73 (Pubitemid 38698361)
38. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009 ; 16: 605-11